MKGAF - MERCK Kommanditgesellschaft auf Aktien

Other OTC - Other OTC Delayed Price. Currency in USD
-0.86 (-0.76%)
At close: 3:47PM EST
Stock chart is not supported by your current browser
Previous Close113.20
Bid0.00 x 0
Ask0.00 x 0
Day's Range112.34 - 116.00
52 Week Range96.00 - 120.95
Avg. Volume296
Market Cap49B
Beta (5Y Monthly)0.54
PE Ratio (TTM)21.68
Earnings DateN/A
Forward Dividend & Yield1.40 (1.24%)
Ex-Dividend Date2019-04-29
1y Target EstN/A
  • Thiel Marks Palantir’s Asia Push with $150 Million Japan Venture

    Thiel Marks Palantir’s Asia Push with $150 Million Japan Venture

    (Bloomberg) -- In a rare show of public support, Palantir Technologies Inc.’s co-founder and chairman Peter Thiel pitched the power of the data-mining company during a splashy Tokyo event marking its formal entry into Asia.The billionaire entrepreneur was in Japan Monday to unveil a $150 million, 50-50 joint venture with local financial services firm Sompo Holdings Inc., Palantir Technologies Japan Co. The new company will target government and public sector customers, emphasizing health and cybersecurity initially. Like IBM Corp. and other providers, Palantir’s software pulls together a range of data provided by its customers, mining it for patterns and displaying connections in easy-to-read spiderweb-like graphics that might otherwise get overlooked.“We can learn a lot from Japan, that some of the challenges that Japan has with its aging population are the ones all countries of the West are going to have in the years ahead,” Thiel said at a briefing in Tokyo. “We hoped this can be a two-way exchange.”The push into Asia comes at a critical time for the 15-year-old company. Despite having long-term, billion-dollar contracts with BP Plc., Merck KGaA and others in more than a dozen countries worldwide, Palantir has never turned an annual profit. Under the leadership of Thiel and the management of Chief Executive Officer Alex Karp, Palantir has long emphasized engineering over sales and revenue, a focus that has shifted only this year.The company has not set a date for an initial public offering and continues to explore raising additional funding from private investors. Palantir spokeswoman Lisa Gordon told Bloomberg there are no formal conversations underway and disputed reports that Palantir is considering a deal with Softbank Group Corp. or that the company is seeking as much as $3 billion in funding at a $30 billion valuation.Valuation is a touchy subject for the Silicon Valley company. Although private investors valued Palantir in 2015 at more than $20 billion, aggressive markdowns by mutual funds and an uncertain IPO timeline have taken a toll. Palantir’s valuation has continued to tumble, with shares trading around $5 a share during the past month, according to data from secondary markets.Palantir is very close to breaking even and will end 2019 either slightly in the black or slightly in the red, Thiel said at the briefing. The company will be “significantly in the black” next year, he added.“The judgment call Palantir has made, as have many other companies in Silicon Valley post 2000, is it is often much better to build businesses in private,” Thiel said. “There is some day in the future when Palantir will go public, but we will try to stay private as long as possible.”Palantir’s public image has taken a beating in recent years. It’s attracted scrutiny from privacy advocates and protesters disturbed by the way Palantir’s software has been used by state and local law enforcement in the U.S., as well as by federal agencies like the Department of Homeland Security while implementing the controversial family separation policy at the U.S. Mexican border.Thiel himself has been a lightning rod for criticism, having helped the election of U.S. President Donald Trump in 2016, a divisive decision even within Palantir. That critique could intensify given he has pledged to support Trump’s 2020 re-election.“I envision supporting President Trump over his likely Democratic nominees,” Thiel said in Tokyo, adding he will determine the exact nature of his support as elections approach.(Updates with comments from news briefing from the third paragraph.)To contact the reporters on this story: Pavel Alpeyev in Tokyo at;Lizette Chapman in San Francisco at lchapman19@bloomberg.netTo contact the editors responsible for this story: Edwin Chan at, Vlad SavovFor more articles like this, please visit us at©2019 Bloomberg L.P.

  • Reuters

    UPDATE 2-Merck KGaA raises 2019 guidance after Versum takeover

    German science and technology company Merck KGaA raised its full-year forecast for sales and adjusted earnings on Thursday after completing the takeover of semiconductor materials maker Versum Materials in October. Merck said 2019 earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for special items, would come in between 4.23 billion euros and 4.43 billion euros ($4.7-$4.9 billion), up from a previous prediction of between 4.15 billion euros and 4.35 billion euros. Shares in Merck were down 1.55% at 0828 GMT.

  • If You Had Bought MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Stock Five Years Ago, You Could Pocket A 47% Gain Today
    Simply Wall St.

    If You Had Bought MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Stock Five Years Ago, You Could Pocket A 47% Gain Today

    Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...

  • MarketWatch

    Merck KGaA, Pfizer drug fails to meet endpoints in gastric cancer trial

    Merck KGaA and Pfizer said Friday that a late-stage clinical trial testing Bavencio as a first-line maintenance treatment for patients with certain forms of gastric cancer failed to meet the study's primary endpoints for survival. The current standard of care is chemotherapy. The German drugmaker and Pfizer formed an alliance in 2014 to develop and commercialize Bavencio, which was first approved by the U.S. Food and Drug Administration in 2017 as a treatment for metastatic Merkel cell carcinoma. Shares of Pfizer have fallen 15.44% year-to-date, while the S&P 500 is up about 23% for the year.

  • Calculating The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)
    Simply Wall St.

    Calculating The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)

    Today we'll do a simple run through of a valuation method used to estimate the attractiveness of MERCK...

  • Reuters

    Merck KGaA lung cancer drug is 3rd on U.S. watchdog's priority lane

    Merck KGaA's prospective lung cancer treatment tepotinib became the third drug against a rare and aggressive subtype of the disease that won U.S. Food and Drug Administration's breakthrough therapy designation. Novartis last week won the breakthrough therapy tag, which puts it on a fast track for regulatory review, for its capmatinib drug. Pfizer's Xalkori drug was given the designation last year.

  • Moody's

    Merck KGaA -- Moody's: Versum shareholders approve acquisition by Merck KGaA

    Merck KGaA ("Merck") announced that its transaction with Versum Materials, Inc ("Versum") had been approved at a special meeting among Versum's shareholders. Merck had signed a definitive agreement to acquire Versum for a consideration of $53 in cash in April this year, notes Moody's.

  • Reuters

    Merck KGaA sees currencies supporting 2019 outlook

    FRANKFURT (Reuters) - Germany's Merck KGaA, which is taking over U.S. electronic chemicals maker Versum Materials, said it expected a slight tailwind from foreign exchange effects supporting earnings growth ...


    Keeley Funds Comments on Versum Materials

    Guru stock highlight

  • Reuters

    UPDATE 2-European shares hit by U.S. tariff threat, growth jitters (April 9)

    European shares slid on Tuesday, with most sectors falling after the United States threatened to slap tariffs on goods from the European Union, with worries compounded by the IMF cutting its global growth forecast. The U.S. Trade Representative proposed a list of European Union products late on Monday on which to slap tariffs in retaliation to more than $11 billion of EU subsidies to Airbus the World Trade Organization has found cause "adverse effects" to the United States.

  • Benzinga

    Merck KGaA Signs Versum Buyout Deal; Entegris Receives Termination Payment

    The business combination received unanimous approval from the boards of the German pharmaceutical company and Versum, Merck said in a Friday press release. Versum is a supplier of process chemicals, gases and semiconductor manufacturing equipment.

  • Reuters

    Merck KGaA clinches $6.5 billion Versum takeover in bet on electrochemicals

    Germany's Merck KGaA sealed a $6.5 billion (4.9 billion pounds) takeover deal with Versum Materials after overturning a deal it had agreed with rival bidder Entegris. A bet on a recovery in electronic materials markets for semiconductor makers, the transaction will boost the share of profit that diversified Merck derives from high-tech chemicals to 27 percent from 19 percent previously. Merck, also maker of pharmaceuticals and biotech production gear, this week won the backing of Versum's board for its $53-per-share offer, lifted from $48 previously, having been spurned for weeks.

  • Benzinga

    Versum Materials Says Revised Merck KGaA Buyout Proposal 'Superior' To Entegris Offer

    Versum Materials, Inc . (NYSE: VSM ) announced Monday that it received a revised proposal from Merck KGaA to acquire Versum for $53 per share, up from Merck's prior $48-per-share proposal on Feb. 27.  ...

  • Merck KGaA wins Versum's support for sweetened $6.5 billion offer

    Merck KGaA wins Versum's support for sweetened $6.5 billion offer

    Merck KGaA won the backing of Versum's board for a sweetened $6.5 billion takeover proposal, overturning an agreed merger with rival Entegris as it bets on a recovery in electronic materials markets. "This proposal constitutes a 'Superior Proposal' as defined in Versum's previously announced merger agreement with Entegris, Inc.," Versum said in a statement on Monday. On a per share basis, Germany's Merck offered $53, up from $48 previously, after reviewing business data and following meetings between Merck Chief Executive Stefan Oschmann and Versum Chairman Seifi Ghasemi, filings showed.

  • Reuters

    Merck KGaA raises offer for Versum Materials to $53 per share

    Versum Materials Inc said on Monday that Merck KGaA had raised its offer for the company to $53 per share from $48. Merck had launched a hostile $5.9 billion all-cash takeover offer for Versum last month ...

  • Pfizer's New Lung Cancer Drug Vizimpro Gets EU Approval

    Pfizer's New Lung Cancer Drug Vizimpro Gets EU Approval

    Pfizer's (PFE) new lung cancer medicine, Vizimpro (dacomitinib) gets approval in EU after being approved in the United States last September.

  • Merck KgaA's (MKGAF) MS Drug Mavenclad Gets FDA Approval

    Merck KgaA's (MKGAF) MS Drug Mavenclad Gets FDA Approval

    Merck KaaA (MKGAF) announces approval of Mavenclad in the United States as a treatment for multiple sclerosis. The drug is already approved in other countries including Europe.

  • Merck KGaA CFO on M&A Hiatus, Third-Quarter Earnings

    Merck KGaA CFO on M&A Hiatus, Third-Quarter Earnings

    Nov.15 -- Marcus Kuhnert, chief financial officer of Merck KGaA, said the company will focus on integrating Versum Materials before it starts looking for a new takeover target. He spoke Nov. 14 on "Bloomberg Markets: European Open" after the firm posted third-quarter earnings.